- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-SPY2/ SPRY2/ IGAN3 monoclonal antibody
Anti-SPY2/ SPRY2/ IGAN3 antibody for FACS & in-vivo assay
Go to SPRY2/SPRY2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP1709-Ab-1/ GM-Tg-hg-MP1709-Ab-2 | Anti-Human SPRY2 monoclonal antibody | Human |
| GM-Tg-rg-MP1709-Ab-1/ GM-Tg-rg-MP1709-Ab-2 | Anti-Rat SPRY2 monoclonal antibody | Rat |
| GM-Tg-mg-MP1709-Ab-1/ GM-Tg-mg-MP1709-Ab-2 | Anti-Mouse SPRY2 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP1709-Ab-1/ GM-Tg-cynog-MP1709-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SPRY2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP1709-Ab-1/ GM-Tg-felg-MP1709-Ab-2 | Anti-Feline SPRY2 monoclonal antibody | Feline |
| GM-Tg-cang-MP1709-Ab-1/ GM-Tg-cang-MP1709-Ab-2 | Anti-Canine SPRY2 monoclonal antibody | Canine |
| GM-Tg-bovg-MP1709-Ab-1/ GM-Tg-bovg-MP1709-Ab-2 | Anti-Bovine SPRY2 monoclonal antibody | Bovine |
| GM-Tg-equg-MP1709-Ab-1/ GM-Tg-equg-MP1709-Ab-2 | Anti-Equine SPRY2 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP1709-Ab-1/ GM-Tg-hg-MP1709-Ab-2; GM-Tg-rg-MP1709-Ab-1/ GM-Tg-rg-MP1709-Ab-2; GM-Tg-mg-MP1709-Ab-1/ GM-Tg-mg-MP1709-Ab-2; GM-Tg-cynog-MP1709-Ab-1/ GM-Tg-cynog-MP1709-Ab-2; GM-Tg-felg-MP1709-Ab-1/ GM-Tg-felg-MP1709-Ab-2; GM-Tg-cang-MP1709-Ab-1/ GM-Tg-cang-MP1709-Ab-2; GM-Tg-bovg-MP1709-Ab-1/ GM-Tg-bovg-MP1709-Ab-2; GM-Tg-equg-MP1709-Ab-1/ GM-Tg-equg-MP1709-Ab-2 |
| Products Name | Anti-SPRY2 monoclonal antibody |
| Format | mab |
| Target Name | SPRY2 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-SPRY2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species SPY2/ SPRY2/ IGAN3 VLP (virus-like particle) (Products Developing) |
| Cytokine | GM-Tg-g-MP1709-Ag-1 | sprouty homolog 2 (Drosophila) (SPRY2) protein |
| ORF Viral Vector | pGMLP000306 | human SPRY2 Lentivirus plasmid |
| ORF Viral Vector | vGMLP000306 | human SPRY2 Lentivirus particle |
| ORF Viral Vector | pGMAD000520 | human SPRY2 Adenovirus plasmid |
| ORF Viral Vector | vGMAD000520 | human SPRY2 Adenovirus particle |
| ORF Viral Vector | pGMLPm001024 | mouse Spry2 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm001024 | mouse Spry2 Lentivirus particle |
Target information
| Target ID | GM-MP1709 |
| Target Name | SPRY2 |
| Gene ID | 10253,24064,306141,702103,485504,101088453,539090,100050086 |
| Gene Symbol and Synonyms | hSPRY2,IGAN3,sprouty2,SPRY2 |
| Uniprot Accession | O43597,Q08E39 |
| Uniprot Entry Name | SPY2_HUMAN,SPY2_BOVIN |
| Protein Sub-location | Transmembrane Protein |
| Category | Cytokine Target |
| Disease | Cancer |
| Gene Ensembl | ENSG00000136158 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: SPRY2, gene name: SPRY2, also named as IGAN3, hSPRY2. This gene encodes a protein belonging to the sprouty family. The encoded protein contains a carboxyl-terminal cysteine-rich domain essential for the inhibitory activity on receptor tyrosine kinase signaling proteins and is required for growth factor stimulated translocation of the protein to membrane ruffles. In primary dermal endothelial cells this gene is transiently upregulated in response to fibroblast growth factor two. This protein is indirectly involved in the non-cell autonomous inhibitory effect on fibroblast growth factor two signaling. The protein interacts with Cas-Br-M (murine) ectropic retroviral transforming sequence, and can function as a bimodal regulator of epidermal growth factor receptor/mitogen-activated protein kinase signaling. This protein may play a role in alveoli branching during lung development as shown by a similar mouse protein. [provided by RefSeq, Jul 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
